New Patent Strengthens AroCell’s Intellectual Property Portfolio
AroCell AB is pleased to announce the Japanese Patent Office's confirmation of a new patent (patent application number: 2021-564698) for an innovative use of the TK1 protein in detecting and categorizing respiratory infections.
This patent, which was previously granted by the European Patent Office (EP3966568) in July 2024, signifies a major milestone for AroCell. It relates specifically to the use of serum thymidine kinase 1 (sTK1) to predict and diagnose Mycoplasma pneumonia caused by M. pneumoniae. Additionally, the TK1 protein levels can assist in determining the type of respiratory infection: if the TK1 levels are above the threshold, it indicates Mycoplasma pneumonia; if they are below the threshold, it suggests pneumonia caused by a different bacterium.
The research that supports the patent demonstrates an exciting opportunity to extend the use of our TK1 test to include respiratory infections. By strengthening the protection of our test, we facilitate further commercialization and broader use of our TK1 marker.